For instance, T-DM1, an anti-HER2 antibody drug conjugate, has been approved by the FDA and the European Medicines Agency (EMA) for adjuvant therapy in patients with HER2-positive metastatic disease, who have previously undergone treatment with trastuzumab and taxane [6]. This evidence concerns the gene ERBB2 and metastatic neoplasm.